Pharmaceutical Executive October 2, 2024
Mike Hollan

Immorta Bio’s president discusses the company’s work with age-related diseases.

It’s no secret that as people get older, they face more health risks at a higher rate. Dr. Thomas Ichim, president and chief scientific officer at Immorta Bio, spoke with Pharmaceutical Executive about his company’s work focused on age related diseases and the unique challenges this brings.

Pharmaceutical Executive: What made Immorta decide to focus on aging related diseases?
Dr. Thomas Ichim: We recognized that aging is the primary risk factor for numerous diseases, characterized by the gradual decline of organs and tissues, and an increased likelihood of disease onset and progression, including cancer, cardiovascular disease, metabolic disorders, and neurodegeneration. The field of aging science and longevity technologies has advanced significantly,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Interview / Q&A, Patient / Consumer, Provider, Trends
Dexcom Adds Generative AI Platform to Its Over-the-Counter CGM
Happy Holidays: Is Your Doctor Happy? Are You Happy With Your Doctor?
Health for the Holidays: 3 Strategies for Empowering Medication Adherence
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old
Memory Loss Is Not Always Dementia. A Neurologist Explains

Share This Article